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Abstract: Background: The aim of this study was to compare the pharmacokinetics of antituberculosis drugs in patients with 
pulmonary tuberculosis (PTB) and in patients with PTB and HIV during the first 24 h of treatment. Methods: Designed a case-control 
study, it compares the pharmacokinetics of first line antituberculous drugs, in HIV-positive (cases) and HIV-negative (control) patients 
both presenting with pulmonary tuberculosis. Blood samples were collected before and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 8, 12 and 24 h 
after administration of drugs. Drugs plasma levels were tested using HPLC assays. Results: Fourteen HIV positive (7 males and 7 
females) and 17 HIV negative (9 males and 8 females) enrolled. Rifafour, a combination tablet including rifampicin, isoniazid, 
pyrazinamide and ethambutol was used in HIV positive patients, CD4 counts were significantly lower, renal function mildly decreased 
in 85% patients and moderately decreased in 7% patients. Liver function was normal in both groups. None of these patients was on 
other drug therapy. In the HIV positive group isoniazid T1/2 and AUC were decreased and Cl increased whereas Tmax and Cmax were 
unchanged. Pyrazinamide Tmax and Cmax were significantly decreased in HIV positive patients and no significant changes were 
noticed in the T1/2, AUC and CL. Conclusion: The study suggest that ethambutol, pyrazinamide and rifampicin pharmacokinetics was 
not affected by HIV infection and that isoniazid disposition is affected by HIV. 
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1. Introduction  
Tuberculosis (TB), in sub-Saharan Africa, remains a 
leading cause of mortality in HIV infected patients and 
is the leading cause of death in South Africa where the 
life expectancy is only 49 years of age. The country has 
the highest incidence of HIV/AIDS world wide with an 
estimated 5.7 million people infected in 2009 [1, 2].  
Co-infection of HIV/AIDS patients with TB is a 
substantial health problem. The cure rate in 2008 of 
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new smear-positive patients with TB in South Africa 
was 64%. Therapeutic response is influenced by the 
method of administration with Directly Observed 
Treatment (DOT) estimated to have averted 8 million 
deaths related to TB [3]. Appropriate management of 
TB in South Africa is particular important because of 
the high incidence of HIV, a known risk factor for 
development of TB, and the high rates of MDR-TB 
with over 6,000 cases expected to be treated in South 
Africa in 2010.  
Drug treatment of tuberculosis consists of 2 months 
of isoniazid, refiampin, pyrazinamide and ethambutol 
followed by 4 months of rifampin and isoniazid [4]. 
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Therapeutic response is related to serum concentrations 
of drugs received with poor outcomes associated with 
low pyrazinamide and isoniazid concentrations [5, 6]. 
Lower treatment outcomes are seen in patients 
co-infected with HIV [7], which may explain why the 
cure rates in South Africa are low. 
There have been a few studies that have investigated 
the influence of AIDS on the absorption of drugs used 
to treat tuberculosis. Some authors concluded that drug 
malabsorption may contribute to the emergence of 
acquired drug resistance [7–10]; and they have 
advocated for routine therapeutic drug monitoring of 
antituberculous drugs in HIV-infected patients, 
particularly those with advanced HIV disease [7–10]. 
Other studies found that the call for screening of 
antimycobacterial drug levels in HIV-infected patients 
with pulmonary tuberculosis is still premature since no 
impairment in the bioavailability of antituberculosis 
drugs was found [11, 12]. 
The aim of this study was to describe the 
pharmacokinetics of the first line anti-tuberculosis (TB) 
drugs during the first 24 hours after drug administration 
in patents infected with pulmonary tuberculosis (PTB) 
and compare the pharmacokinetic parameters obtained 
in patients co-infected with PTB and HIV. 
2. Patients and Methods 
2.1 Study Design, Subjects, Inclusion and Exclusion 
Criteria 
Designed a case-control study, the study compares 
the pharmacokinetics of first line antituberculous drugs, 
in HIV-positive (cases) and HIV-negative (control) 
patients both presenting with pulmonary tuberculosis. 
The study involved male and female patients without 
previous history of TB, 18 to 60 years old, with sputum 
microbiology test positive for Mycobacterium 
tuberculosis (MTB) which was sensitive to rifampicin 
(RIF), isoniazid (INH), ethambutol (ETH) and 
pyrazinamide (PZA). Patients were recruited from their 
home area TB clinics where they had just been tested 
for HIV after counseling. After informed and written 
consent to join the study, patients were admitted to the 
Karl Bremer Hospital in Cape Town (South Africa), in 
the evening before the start of TB treatment. They were 
excluded from the study on request by the patient, if 
they were critically ill and in case of previous exposure 
to anti-TB drugs. Other exclusion criteria included the 
presence of chronic disease such as diabetes mellitus, 
hypertension and cardiac failure, as determined by 
physical examination. 
2.2 Drugs Used 
For the initial phase of treatment (2 months) 
Rifafour® e-200 tablets were used. Each tablet 
contains rifampicin (RIF) 120 mg, isoniazid (INH) 60 
mg, pyrazinamide (PZA) 300 mg and ethambutol (ETH) 
200 mg. Patients weighing 30–50 kg body weight (BW) 
received 4 tablets Rifafour® e-200 daily dose. Those 
with a body weight (BW) > 50 kg received 5tablets 
Rifafour® e-200 daily dose. For the continuation phase 
of treatment Rifinah ® – 150 and Rifinah ® – 300 were 
used. Each Rifinah ® – 150 tablet contains RIF 150 mg 
and INH 100 mg. Each Rifinah ® – 300 tablet contains 
RIF 300 mg and INH 150 mg. Patients weighing less 
than 50 kg received 3 tablets of Rifinah ® – 150 and 
those with a BW ≥ 50 kg received 2 tablets of Rifinah 
® – 300. Tablets were taken in front of a nurse every 
day, five days a week (Monday to Friday). Each patient 
was also given pyridoxine 25 mg daily in order to 
prevent peripheral neuropathy due to INH. All tablets 
were supplied by Aventis Pharma (Pty) Ltd, 2 Bond 
Street, Midrand 1685, South Africa. The acetylation 
status of our patients was unknown.  
2.3 Collection of Blood Samples 
The following morning, after an 8-hour overnight 
fast, blood samples were collected for base line tests 
including liver function tests (LFTs), renal function 
tests (RFTs), full blood count (FBC), CD4 counts and 
plasma concentrations of the anti-TB drugs. Rifafour 
was administered to patients for the first time using the 
dosages recommended by the Department of Health. 
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Then blood samples were collected for TB drugs 
plasma levels determination at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 
4, 4.5, 8, 12 and 24 hours after drug administration. 
Patients were served the same breakfast 1 hour after the 
beginning of the treatment. They were also offered the 
same meal at lunch and super time. The following 
morning, the 24 hours blood sample for TB drug 
plasma levels determination was collected before 
breakfast and administration of the following morning 
anti-TB drugs. Blood samples for determination of TB 
drugs plasma levels were collected in a heparinized 
vacutainer tube from an intravenous catheter fixed on a 
forearm vein of the patient prior to dosing and 
centrifuged immediately, with the plasma stored in a 
minus 20˚C freezer for no more than 12 hours. 
Thereafter, it was stored in a minus 80˚C deep freezer 
until analysis.  
2.4 Laboratory Tests 
The following laboratory tests were conducted at the 
National Laboratory Services  
(NHLS) Green Point Lab (Cape Town–South Africa) 
for each patient: liver function tests (LFTs), renal 
function tests (RFTs), full blood counts (FBC), sputum 
microscopy after Auromine or Ziehl-Neelsen stains. If 
mycobacteria were observed, susceptibility tests were 
determined forall first — line anti TB agents mentioned 
above HIV test (Elisa) was done at the University of 
Cape Town (UCT) Virology Department for each 
patient. Plasma levels were performed using high 
performance liquid chromatography (HPLC) assay 
methods. The lower limit of quantification for all four 
drugs was 0.05 µg/ml. The linear range for isoniazid 
and rifampicin was 0.05–30 µg/ml and for 
pyrazinamide it was 0.05–100 µg/ml. All four drugs 
were measured from the same assay run. 
2.5 Determination of Pharmacokinetic Parameters 
After determination of rifampicin, isoniazid, 
pyrazinamide and ethambutol plasma concentrations, 
the plasma concentration-time profile for each drug by 
patient was plotted using Graph Pad Prism program. 
Drugs pharmacokinetic parameters were calculated 
based on the non-compartmental analysis (NCA) as 
follows: 
2.5.1 Maximum Concentration and the Time to 
Reach Maximum Concentration 
The maximum concentration (Cmax) and the time to 
reach the maximum concentration (Tmax) were obtained 
directly from the plasma concentration-time profile. 
2.5.2 Half-life  
The half-life (T½) was calculated using the formula:  
T½ = 0.639/Ke and Ke was determined from the 
terminal slope of the ln-concentration vs time curve. 
2.5.3 The Area under the Plasma 
Concentration-Time Curve  
The area under the plasma concentration-time curve 
from zero to 24 hours (AUC0-24) was calculated by the 
trapezoidal method using Graph Pad Prism software.  
2.5.4 The Total Body Clearance  
The apparent total body clearance (Cltot) was 
calculated using the following formula: Cltot = Dose/ 
AUC0-24. Low Cmax values were defined using the 
following method reported by Jordan W. Tapero et al. 
[7]: isoniazid, < 3 µg/mL (300 mg dose); rifampicin, 
<8 µg.mL (weight –adjusted dose, 450 or 600 mg); 
pyrazinamide, <35 µg/mL (median dose, 35 mk/kg); 
and ethambutol, <2 µg/mL (median dose, 21 mk/kg).  
Very low Cmax values were defined as follows: 
isoniazid, <2 µg/mL (300 mg dose) or <3 µg/mL (400 
mg dose); rifampicin, <4 µg/mL; pyrazinamide, <20 
µg/mL; and ethambutol, <1 µg/mL. Delayed 
absorption was defined as a Tmax >3 h.  
2.5.5 Ethical and Statistical Considerations 
The study was conducted according to the 
declaration of Helsinki and ICH guidelines. The 
protocol was approved by the ethics committee of the 
University of the Western Cape. Permission to conduct 
the study was granted by the medical superintendent of 
Karl Bremer Hospital. The information obtained 
during the study was treated as confidential. 
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 For each of 4 drugs responses for those who are 
HIV Positive were compared to those who were 
negative on each of the 9 parameters.  Some of the 
parameters are related, so test results are not 
independent. Nevertheless there are many tests being 
done so a more stringent level of significance was used 
(a p value of < 0.01 rather than the customary 0.05 was 
required for significance). In many cases the 
distribution of the measurements was skewed and 
decidedly non-normal. Consequently groups were 
compared using the Wilcoxon Rank Sum test. 
3. Results 
Thirty one (31) patients were involved in the study 
with 14 (7 males and 7 females) patients determined to 
be HIV positive (cases) and seventeen patients (9 males 
and 8 females) HIV negative (control) (Table 1). All of 
them were infected with Mycobacterium tuberculosis 
(MTB) sensitive to anti-TB drugs used. During the 
intensive phase (first 2 months) rifafour, a combination 
tablet including rifampicin 120 mg, isoniazid 60 mg, 
pyrazinamide 300 mg and ethambutol 200 mg, was 
used at the dose of 4 tablets daily five days a week 
(Monday to Friday) for patients under 50 kg body 
weight and 5 tablets daily for patients weighing 50 kg 
and more. 
The median body weight was 54 (range 51–60) kg in 
HIV-positive patients (cases) and 56 (range 51–65) kg 
in HIV-negative patients (control).  
Table 1  Demographics, renal and hepatic function data. 
Characteristics HIV (+) patients (Nb:14) 
HIV (-) patients 
(Nb:17) 
Gender   7 males, 7 females 9 males, 8 females 
Age : average (range) 29.46 (18.5–55) 26.79 (18–36)
CD4 counts: average 
(range) 133.14 (2–332) 
1015.18 ( 674– 
1458) 
GFR: range (ml/min) 
30–59 (12 patients) 
> 90: normal60 – 89 (1 patient) 
>90 (1 patient) 
ALT (normal values: 
5-40) 12 – 35 6 – 25 
AST (normal values: 
5-40) 17 – 39 8 – 30 
GGT (normal values: 0 
– 60) 5 – 55 7 – 35 
As indicated in Table 1, the age distribution is 
similar in both groups. The mean age is 33.06±10.12 in 
HIV negative group (control) and 35.14±12.05 in HIV 
positive group (cases). 
Out of 14 HIV-positive patients, 9 were stage 3 
(WHO staging system) and 5 were stage 4 (WHO 
staging system). The mean CD4 cells was 356.38 and 
the mean period of HIV infection was 5.9 yrs.  
The CD4 counts were significantly lower in the HIV 
positive patients (cases) than in the HIV negative 
patients (control). In the HIV control group, the renal 
function was normal. However, in cases group, the 
renal function was mildly decreased in 85.71% of 
patients, moderately decreased in 7.14% of patients 
and normal in 7.14% of patients. The hepatic function 
tests were normal in both groups. None of these 
patients was on other drug therapy. 
Tables 2a, 2b, 2c and 2d provide the descriptive 
statistics for the pharmacokinetic parameters for the 
test drugs in HIV positive and HIV negative patients. 
In general the presence of HIV did not impact the 
disposition of ethambutol, pyrazinamide and 
rifampicin. The one exception was isoniazid which 
showed a modest effect of HIV on its disposition. A 
statistical reduction in Tmax in HIV positive patients 
was observed and borderline changes in half-life, 
AUC0-24 and Cl. It appears that the presence of HIV 
may modestly decrease AUC and half-life which is 
consistent with either an observed increase in clearance 
or reduction in bioavailability. 
4. Discussion and Conclusion 
The  current  study  evaluated the  disposition of 
 
Table 2a  Pharmacokinetic parameters in HIV negative 
and HIV positive patients. 
Ethambutol (1000
mg-dose) HIV-negative HIV-positive 
Statistical 
significance
Subject Number 17 14  
Tmax (h) 2.4 ± 0.32 2.4 ± 0.32 NS 
Cmax (μg/ml) 2.8 ± 0.65 2.8± 0.77 NS 
T½ (h) 4.5 ± 0.61 4.4± 0.46 NS 
AUC0-24(μg/h.ml) 11.5 ± 1.5 11.6± 2.9 NS 
Cl (L/h) 88.7 ±11.4 90.5± 20.9 NS 
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Table 2b  Isoniazid pharmacokinetic parameters in HIV 
negative and HIV positive patients. 
Isoniazid (300 




Number 17 14  
Tmax (hrs) 2.5±0.12 2.1±0.21 <0.001 
Cmax (µg/mL) 2.1±0.26 2.2±0.37 NS 
T½ (hrs) 4.8±3.2 3.5±2.6 0.0299 
AUC0-24 
(μg/h.ml) 15.4±9.5 9.6±3.3 0.0365 
Cl (L/hr) 25.4±11.2 34.3±9.8 0.0365 
 
Table 2c  Pyrazinamide pharmacokinetic parameters in 




HIV-negative HIV-positive Statistical significance
Subject 
number 17 14  
Tmax (hrs) 2.5±0.26 2.4±0.43 0.084 
Cmax 
(μg/ml) 61.7±8.6 57.2± 9.8 0.124 
T½ (hrs) 8.8±2.3 9.7±2.6 NS 
AUC0-24 
(μg/h.ml) 698.9±237.4 730.2±194.6 NS 
Cl (L/hr) 2.4±0.98 2.2±0.59 NS 
 
Table 2d  Rifampicin pharmacokinetic parameters in HIV 




negative HIV positive 
Statistical 
significance
  Subject Number 17 14  
  Tmax (hrs) 2.8±0.36 2.7±0.32 NS 
  Cmax (μg/ml) 13.5±2.5 13.7±1.2 NS 
  T ½ (hrs) 6.0±2.9 6.5±2.7 NS 
  AUC0-24 
(μg/h.ml) 95.3±34.8 113.5±49.9 NS 
  Cl (L/hr) 7.1±2.6 6.2±2.5 NS 
 
ethambutol, pyrazinamide, isoniazid and rifampcin in 
patients with active TB who were either HIV-positive 
or HIV-negative. The data suggests that isoniazid 
disposition is affected by HIV with the Tmax and 
AUC0-∞ being lower in patients co-infected with HIV.  
The presence of HIV had no effect in this study on the 
disposition of ethambutol, pyrazinamide or rifampicin. 
Several studies have evaluated the influence of HIV on 
the pharmacokinetics of first line anti-TB drugs. The 
demographic parameters (number, gender balance, 
mean age and mean CD4 lymphocytes count) of 
patients involved in this study are similar to those of 
patients who participated in the previous studies [12, 
15–18]. Ethambutol Cmax, Tmax and half life found in 
this study are similar to those reported in previous 
studies and there is no significant difference between 
HIV-negative and HIV-positive patients [12, 15–18]. 
The presence of HIV does not influence the disposition 
of ethambutol. Isoniazid pharmacoki- netic parameters 
found in this study and those reported previously [12, 
15–18] are quite variable. This could be explained by 
the differences between studies in the incidence of 
rapid and slow acetylators in the population. However, 
for each study, there is no significant difference 
between pharmacokinetic values in HIV-negative and 
HIV-positive patients. Our study does show a modest 
37% reduction in AUC in HIV-positive patients. This 
result is in variance with other studies and does indicate 
the need for additional studies. The AUC that we report 
in HIV-negative patients is very comparable to that 
reported in normal health volunteers that are slow 
acetylators [19]. Whereas the AUC value we reported 
in HIV-positive patients is between that reported for 
rapid and slow acetylators of INH. The differences that 
we report in INH AUC as a function of HIV status 
could very well reflect differences in the number of 
patients who are rapid acetylators between these 
groups. 
In this study, pyrazinamide and rifampicin Tmax, 
Cmax, T1/2 and AUC values are higher than in studies 
previously conducted [12, 15–18]. However, in each 
individual study, there is generally no significant 
difference between HIV-negative and HIV-positive 
patients. The most recent study from Botswana [6] 
reported lower than expected concentrations of 
pyrazinamide and showed that these were related to 
treatment outcomes. This study, however, showed only 
very modest influences (p < 0.04) of HIV infection on 
the disposition pyrazinamide and rifampin. These 
results are not that much different that this study in 
South Africa.   
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In HIV positive patients, renal function was mildly 
decreased in 85.71% of patients and moderately 
decreased in 7.14% of patients. This however did not 
influence the pharmacokinetics of isoniazid, 
ethambutol, pyrazinamide and rifampicin.  
In this study ethambutol and rifampicin 
pharmacokinetics were not affected by HIV infection. 
In the HIV positive group isoniazid T1/2 and AUC were 
decreased and Cl increased whereas Tmax and Cmax 
were unchanged. Pyrazinamide, Tmax and Cmax were 
significantly decreased in HIV positive patients and no 
significant changes were notices in the T1/2, AUC and 
CL. 
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